Nov 12, 2024 / 01:00PM GMT
Craig Collard - Heron Therapeutics Inc - Chief Executive Officer, Director
Total acute care net revenues for the quarter were $7.4 million. [ZYNRELEF] net revenues for the quarter were $6.3 million upon the net revenues for the quarter were $1.1 million.
While we are pleased with our progress, we also knew that we were still transitioning in Q3.
We believe that moving forward, our quarterly growth should start to increase dramatically with the many things we have going on promotionally. These items will not only have an impact on ZYNRELEF but across our entire product portfolio.
Earlier, I spoke about VAN.
And the Nopain Act, both of which will have an impact in 2025.
Right now. We are seeing early results that the Crosslink partnership is beginning to drive growth.
Our team has trained almost 700 crosslink distributors and contractors whose early impact is shown here when a crosslink rep makes a material impact on an account like a key introduction or a trial from a new surgeon.
Our salesforce marked that account as a crosslink account.
Q3 2024 Heron Therapeutics Inc Earnings Call Transcript
Nov 12, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers